Lexicon Pharmaceuticals, Inc. Form 4 Filings

Lexicon Pharmaceuticals director Diane E. Sullivan reported the vesting and exercise of restricted stock units into common shares. On June 3, 2026, 89,312 restricted stock units converted into 89,312 shares of common stock at a stated price of $0.00 per share, reflecting stock-based compensation rather than a market purchase. Following this transaction, Sullivan directly owned 126,122 shares of common stock. Footnotes explain that each restricted stock unit represented a contingent right to receive one share and that the award vested in full on the first anniversary of its grant date.

LEXICON PHARMACEUTICALS director Christopher J. Sobecki exercised restricted stock units into common shares. He converted 89,312 restricted stock units into 89,312 shares of common stock, consistent with each unit representing one share. Following this stock-based compensation event, he directly holds 293,177 shares of common stock.

Lexicon Pharmaceuticals director Ivan Cheung exercised restricted stock units into common shares. On June 3, 2026, Cheung converted 89,312 restricted stock units into 89,312 shares of common stock at a price of $0.00 per share, a non-cash equity award event.

Following the transaction, Cheung directly holds 89,312 common shares and no restricted stock units remain from this grant. Each restricted stock unit represented a contingent right to receive one share of common stock, vesting in full on the first anniversary of the grant date.

LEXICON PHARMACEUTICALS director Sam L. Barker exercised restricted stock units into common shares. On 2026-06-03, 89,312 restricted stock units converted into 89,312 shares of common stock at a stated price of $0.00 per share, reflecting equity compensation rather than an open‑market trade.

Following this conversion, Barker directly owns 213,771 shares of common stock. The footnotes explain that each restricted stock unit represented a contingent right to receive one share of common stock, and that the award vested in full on the first anniversary of its grant date.

LEXICON PHARMACEUTICALS, INC. director Philippe Amouyal exercised restricted stock units into common shares. On June 3, 2026, he converted 89,312 restricted stock units into the same number of common shares at a stated price of $0.00 per share, reflecting a compensation-related vesting rather than a market purchase or sale. After the transaction, he held 374,486 common shares directly. The derivative position in these restricted stock units was fully settled, leaving no remaining units from this grant.

LEXICON PHARMACEUTICALS, INC. director Raymond Debbane exercised restricted stock units into common stock. He converted 89,312 restricted stock units at an exercise price of $0.00 per unit into 89,312 shares of common stock and now holds 1,995,498 shares directly. Entities associated with him hold additional indirect positions of 35,402,689, 5,451,204, 7,362,368 and 1,538,462 common shares as of the reported date.

LEXICON PHARMACEUTICALS, INC. (LXRX) insider group led by Artal entities reported an internal restructuring of their stake. Artal Participations S.a r.l. had previously acquired 408,434.70 shares of Series B convertible preferred stock at $65.00 per share. Each preferred share automatically converted into 50 shares of common stock once shareholder approval and other conditions were satisfied, which occurred on April 30, 2026. As a result, 408,434.70 preferred shares converted into 20,421,735 shares of common stock. Following the conversion, Artal Participations S.a r.l. indirectly holds 175,156,062 shares of common stock, reflecting a large, ongoing position rather than an open-market purchase or sale.

LEXICON PHARMACEUTICALS, INC. director Philippe Amouyal received new equity awards as part of his compensation. On May 1, 2026, he was granted 43,478 stock options to buy common stock at an exercise price of $1.61 per share, expiring on May 1, 2036.

The option vests in three equal annual installments over the first three anniversaries of the grant date. He was also granted 35,714 restricted stock units (RSUs), which vest in full on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock, with no open-market buying or selling reported in this filing.

LEXICON PHARMACEUTICALS director Christopher J. Sobecki received new equity awards as part of his compensation. On May 1, 2026, he was granted stock options for 43,478 shares of common stock at an exercise price of $1.61 per share, vesting in three equal annual installments on each of the first three anniversaries of the grant date. He was also granted 35,714 restricted stock units, which vest in full on the first anniversary of the grant date, with each unit representing a contingent right to receive one share of common stock. These are awards from the company rather than open‑market purchases or sales.

LEXICON PHARMACEUTICALS director Sam L. Barker received new equity awards. On May 1, 2026, he was granted a stock option for 43,478 shares of common stock at an exercise price of $1.61 per share, vesting in three equal annual installments on each of the first three anniversaries of the grant date.

He also received 35,714 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest in full on the first anniversary of the grant date, providing additional equity-based compensation tied to continued service.

Lexicon Pharmaceuticals director Ivan Cheung received new equity awards as part of his compensation. On May 1, 2026, he was granted a stock option for 43,478 shares of common stock at an exercise price of $1.61 per share, expiring on May 1, 2036. This option vests in three equal annual installments over the first three anniversaries of the grant date.

He was also granted 35,714 restricted stock units, each representing a contingent right to receive one share of common stock. These RSUs vest in full on the first anniversary of the grant date. Both awards are reported as directly owned and represent routine, compensation-related acquisitions rather than open-market purchases or sales.

LEXICON PHARMACEUTICALS director Judith L. Swain received new equity awards as part of her compensation. On May 1, 2026, she was granted stock options for 43,478 shares of common stock at an exercise price of $1.61 per share, vesting in three equal annual installments on each of the first three anniversaries of the grant date and expiring on May 1, 2036. She was also granted 35,714 restricted stock units, which vest in full on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock.

LEXICON PHARMACEUTICALS director Diane E. Sullivan received new equity awards as part of her compensation. On May 1, 2026, she was granted stock options covering 43,478 shares of common stock at an exercise price of $1.61 per share, expiring on May 1, 2036. The option vests in three equal annual installments on each of the first three anniversaries of the grant date.

She was also granted 35,714 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock. The RSUs vest in full on the first anniversary of the grant date. These are non-cash, compensation-related grants, with no open-market purchases or sales reported in this filing.

Lexicon Pharmaceuticals director Raymond Debbane received new equity awards. On May 1, he was granted stock options for 43,478 shares of common stock at an exercise price of $1.61 per share, expiring in 2036.

The option vests in three equal annual installments on each of the first three anniversaries of the grant date. He also received 35,714 restricted stock units, which vest in full on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock.

Lexicon Pharmaceuticals senior vice president Wendy McDermott reported multiple equity award transactions involving restricted stock units and common stock. On February 28, 2026, she exercised or converted several blocks of restricted stock units into common shares at a stated price of $0.00 per share, including a tranche of 144,393 restricted stock units that became common stock. Each restricted stock unit represents the right to receive one share of common stock, and the units vest in three equal annual installments each February 28 following the grant year.

On the same date, 68,107 common shares were withheld at $1.47 per share to satisfy tax withholding obligations, a non‑market transaction classified as a tax‑withholding disposition. After these transactions, McDermott continued to hold common stock directly, reflecting equity compensation rather than open‑market trading.

LEXICON PHARMACEUTICALS, INC. senior vice president Rachel Yap Martens reported equity compensation activity involving restricted stock units and common shares. On February 28, 2026, she exercised 67,090 restricted stock units, converting them into 67,090 shares of common stock at a price of $0.00 per share.

In a related tax event on the same date, 35,826 common shares were disposed of at $1.47 per share to satisfy tax withholding obligations, as described in the footnotes. After these transactions, she held 31,264 shares of common stock and 134,180 restricted stock units directly. Each restricted stock unit represents the right to receive one share of common stock and vests in three equal annual installments each February 28 following the grant year.

LEXICON PHARMACEUTICALS, INC. Senior Vice President and Chief Medical Officer Craig B. Granowitz reported multiple equity award transactions involving restricted stock units and common stock on February 28, 2026.

He exercised or converted restricted stock units into common shares in three separate transactions of 35,790, 74,226, and 202,260 restricted stock units, each at a stated price of $0.00 per unit. Each restricted stock unit represents a contingent right to receive one share of common stock, and these units vest in three equal annual installments on February 28 of each of the three years following the year of grant.

Corresponding non-derivative entries show acquisitions of common stock in matching amounts of 35,790, 74,226, and 202,260 shares, reflecting the settlement of those restricted stock units. A separate transaction disposed of 109,098 shares of common stock at $1.47 per share through withholding of a portion of the issued shares by the company to satisfy the reporting person’s tax withholding obligations. After these transactions, the reporting person directly owned 323,430 shares of common stock.

LEXICON PHARMACEUTICALS, INC. senior vice president of Discovery, Suma Gopinathan, reported multiple equity compensation transactions. On February 28, 2026, she acquired common stock through the exercise and conversion of restricted stock units in blocks of 14,000, 20,310 and 65,640 shares, each at a conversion price of $0.0000 per share. A separate transaction disposed of 24,338 shares of common stock at $1.4700 per share to cover tax withholding obligations, leaving her with 150,132 directly held common shares.

LEXICON PHARMACEUTICALS, INC. senior vice president Lisa DeFrancesco reported equity award activity on common stock. On February 28, 2026, she acquired shares through the exercise and conversion of restricted stock units, including 24,674 and 128,190 units, each representing a right to one common share. A separate transaction disposed of 74,572 common shares at $1.47 per share to satisfy tax withholding obligations, leaving her with directly owned common shares as reported in the filing.

LEXICON PHARMACEUTICALS SVP and General Counsel Brian T. Crum reported multiple exercises of restricted stock units into common stock on February 28, 2026. These were non-cash conversions at $0.00 per share, increasing his directly held common shares. The company also withheld 105,019 common shares at $1.47 per share to cover tax obligations related to the equity awards.

Lexicon Pharmaceuticals SVP & CFO Scott M. Coiante reported equity award activity. On February 28, he acquired 160,237 shares of common stock through the exercise of restricted stock units at no cost, while 54,881 shares were withheld by the company to cover tax obligations. Following these transactions, he directly owns 105,356 shares of common stock and 320,473 restricted stock units, each representing the right to receive one share as they vest over time.

LEXICON PHARMACEUTICALS, INC. Chief Executive Officer Michael Exton reported equity award activity involving restricted stock units and common stock on February 28, 2026. He exercised or converted 503,263 restricted stock units, receiving an equivalent number of common shares at a stated price of $0.00 per share.

In a related tax-withholding disposition, 204,831 common shares were withheld by the company at $1.47 per share to satisfy withholding obligations. Following these transactions, Exton directly held 1,006,527 restricted stock units and 298,432 common shares. The footnotes clarify that each restricted stock unit converts into one share and that vesting occurs in three equal annual installments after grant.

LEXICON PHARMACEUTICALS director Raymond Debbane reported an open-market purchase of company stock. He bought 2,000 shares of common stock at a price of $1.49 per share, bringing his directly held stake to 1,906,186 shares.

The filing also lists indirect holdings in Lexicon Pharmaceuticals common stock through various affiliated investment entities, including 1,538,462 shares held by Avicenna Life Sci Master Fund LP and related parties, 7,362,368 shares by Invus Public Equities, L.P. and related parties, 5,451,204 shares by Invus US Partners, LLC and related parties, and 35,402,689 shares by Invus, L.P. and related parties.

Lexicon Pharmaceuticals director Raymond Debbane reported an open-market purchase of 100,000 shares of common stock at $1.47 per share. Following this buy, he directly holds 1,904,186 shares. The filing also lists additional indirect holdings through Avicenna Life Sci Master Fund LP and several Invus investment entities.

Lexicon Pharmaceuticals director Raymond Debbane reported buying 150,000 shares of common stock in open-market transactions. On February 19, he purchased 50,000 shares at a weighted average price of $1.4393 per share, and on February 20 he bought 100,000 shares at a weighted average price of $1.4779 per share.

After these purchases, his directly owned stake increased to 1,804,186 common shares. The filing also reports additional common stock positions as indirectly owned through entities including Avicenna Life Sci Master Fund LP, Invus Public Equities, L.P., Invus US Partners, LLC, and Invus, L.P.

Artal Participations S.a r.l., a major holder in Lexicon Pharmaceuticals (LXRX), reported receiving an additional 41,289.58 shares of Lexicon’s Series B Convertible Preferred Stock at $65.00 per share on February 17, 2026. This purchase was made under a preferred stock purchase agreement tied to the underwriter’s partial exercise of its option to buy additional Lexicon common stock in an underwritten public offering.

Each share of this preferred stock will automatically convert into 50 shares of common stock once shareholders approve the conversion and other stated conditions are satisfied; until then, the shares are not convertible. After this transaction, Artal Participations S.a r.l. holds a total of 408,434.70 shares of Series B Convertible Preferred Stock indirectly, with related Artal entities and their principals disclaiming beneficial ownership except for any pecuniary interest described.

Lexicon Pharmaceuticals director Raymond Debbane reported open-market purchases of 268,497 shares of common stock over three days. He bought 57,952 shares on February 13 at a weighted average price of about $1.3093, 76,857 shares on February 17 at about $1.3082, and 133,688 shares on February 18 at about $1.32 per share, all in multiple transactions within narrow intraday price ranges. After these purchases, his directly held stake increased to 1,654,186 shares of Lexicon common stock. The filing also lists indirect ownership positions held through Avicenna Life Sci Master Fund LP and several Invus-affiliated entities, with millions of additional shares reported as indirectly owned.

Lexicon Pharmaceuticals insider compensation grant: SVP of Human Resources Wendy McDermott received equity awards on February 12, 2026. She acquired 250,200 restricted stock units, each representing a contingent right to one share of common stock, all held directly after the grant.

She was also granted stock options for 375,300 shares of common stock at an exercise price of $1.37 per share, also held directly. The restricted stock units vest in three equal installments each February 28 in the three years after the grant year, while the options vest 25% on the first anniversary of grant and then 1/48th per month with continued service.

Lexicon Pharmaceuticals reported that SVP, Partnerships & Corporate Strategy Rachel Yap Martens received new equity awards on February 12, 2026. She was granted 193,740 restricted stock units, each representing one future share of common stock, and a stock option for 290,620 shares at an exercise price of $1.37 per share.

The restricted stock units vest in three equal installments on February 28 of each of the three years after the grant year. The stock option vests 25% on the first anniversary of grant, then in equal monthly installments over the following three years, subject to continued service.

Lexicon Pharmaceuticals executive Craig B. Granowitz, SVP and Chief Medical Officer, reported new equity awards. On February 12, 2026, he received 346,610 restricted stock units, each representing one share of common stock, and a stock option for 519,920 shares with a $1.37 exercise price.

The restricted stock units vest in three equal installments on February 28 of each of the three years following the grant year. The option vests 25% on the first anniversary of grant, with the remaining 75% vesting in equal monthly installments over the next 36 months, conditioned on continued service.

Lexicon Pharmaceuticals granted equity awards to senior vice president of discovery Suma Gopinathan. On February 12, 2026, she acquired 238,450 restricted stock units, each representing one share of common stock, and a stock option for 357,680 shares at an exercise price of $1.37 per share.

The RSUs vest in three equal installments on February 28 of each of the three years following the grant year. The option vests 25% on the first anniversary of grant, then 1/48th of the shares each month of continued service until fully vested by February 12, 2036.

Lexicon Pharmaceuticals, Inc. reported equity awards to senior vice president Lisa DeFrancesco. On February 12, 2026, she received 257,530 restricted stock units, each representing a right to one share of common stock, and 386,300 stock options with a $1.37 exercise price.

The restricted stock units vest in three equal installments on February 28 of each of the three years after the grant year. The stock options vest 25% on the first anniversary of grant, with the remaining portion vesting monthly over the following three years, contingent on continued service.

Lexicon Pharmaceuticals executive Brian T. Crum, SVP, General Counsel and Secretary, reported equity awards on February 12, 2026. He was granted 299,710 restricted stock units, each representing the right to receive one share of common stock as they vest.

The restricted stock units vest in three equal installments on February 28 of each of the three years following the grant year. Crum was also granted a stock option for 449,560 shares at an exercise price of $1.37 per share, vesting 25% after one year and the remainder in equal monthly installments over the next three years.

Lexicon Pharmaceuticals SVP and CFO Scott M. Coiante received new equity awards as part of his compensation. On February 12, 2026, he was granted 272,680 restricted stock units, each representing a contingent right to one share of common stock. These RSUs vest in three equal installments on February 28 of each of the three years after the grant year.

On the same date, he also received 409,020 stock options with an exercise price of $1.37 per share, expiring on February 12, 2036. The option vests 25% on the first anniversary of grant, then in equal monthly installments over the following three years, all held as direct ownership.

Lexicon Pharmaceuticals’ Chief Executive Officer and director Michael Exton reported equity awards dated February 12, 2026. He received 862,440 restricted stock units, each representing a right to one share of common stock. These restricted stock units vest in three equal installments on February 28 of each of the three years following the grant year.

He was also granted a stock option for 1,293,670 shares of common stock at an exercise price of $1.37 per share. The option vests 25% on the first anniversary of the grant date and then 1/48th of the shares each month of continued service thereafter.

Lexicon Pharmaceuticals disclosed significant share purchases by investment entities tied to Invus and Artal as part of a financing that closed on February 2, 2026. Artal Participations S.a r.l. agreed to buy 22,400,000 common shares at $1.30 per share, assigning the right to purchase 3,846,154 of those shares to Invus Public Equities, L.P., which bought them directly from Lexicon at the same price. Avicenna Life Sci Master Fund LP purchased 1,538,462 common shares as part of an underwritten public offering.

Artal Participations S.a r.l. also agreed to purchase 367,145.12 shares of Series B Convertible Preferred Stock at $65.00 per share and obtained the right to buy up to an additional 94,854.88 preferred shares at the same price. Each preferred share will automatically convert into 50 common shares once shareholder approval is obtained and specified conditions are met; until then, the preferred shares are not convertible. The filing notes complex ownership chains among Artal, Invus and related entities, and each reporting person disclaims beneficial ownership of securities held by the others beyond its pecuniary interest.